ArticleHeliyon2025
Blood-based biomarkers derived from tumor-informed DNA methylation analysis for lung adenocarcinoma.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objective: To identify robust markers of lung adenocarcinoma (LUAD) using DNA methylation profiles from blood samples informed by tissue lung adenocarcinoma. Methods: This study analyzed 56 LUAD blood samples from patients attending clinic at Siriraj Hospital, Thailand and 51 samples from healthy participants, using 644 tumor and 59 normal tissue methylome datasets from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases for candidate gene identification. We performed comparative analysis to identify DNA methylation (DNAm) changes present in tumors that are also observable in blood, to be taken forward for validation. Results: DNAm profiling of lung tumor datasets identified 59,639 differentially methylated positions (DMPs), of which 17,251 exhibited a negative correlation with gene expression. In blood samples, 46,680 DMPs were identified among LUAD patients, which were enriched in pathways associated with the ribosome, spliceosome, cell cycle, ubiquitin mediated proteolysis and nucleocytoplasmic transport. Comparative analysis revealed a two DMP epigenetic signature of matching changes in both tissue and blood. This signature offered high diagnostic performance in distinguishing LUAD from normal lung tissue (AUC: 0.77-0.91) and in blood samples from LUAD patients (AUC:0.92-0.96). Similarly high performance was observed in two independent tissue validation datasets (AUC:0.90-0.92). Conclusions: Our novel two DMP signatures offer robust performance in both lung tissue and blood for the identification of LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.